AI assistant
JOHNSON & JOHNSON — Director's Dealing 2025
Oct 21, 2025
29750_dirs_2025-10-20_30875551-b3f0-48ed-8aa0-784a27723a22.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2025-10-17
Reporting Person: REED JOHN C (EVP, Innovative Medicine, R&D)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-10-17 | Common Stock | M | 21721 | $157.92 | Acquired | 32379 | Direct |
| 2025-10-17 | Common Stock | S | 21721 | $192.7072 | Disposed | 10658 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-10-17 | Employee Stock Options (Right to Buy) | $157.92 | M | 21721 | Disposed | 2034-02-15 | Common Stock (21721) | Direct |
Footnotes
F1: This transaction was executed in multiple trades at prices ranging from $192.69 to $192.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date.